<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Barlesi, Fabrice</style></author><author><style face="normal" font="default" size="100%">Thomas, Roman K.</style></author><author><style face="normal" font="default" size="100%">Gandara, David R.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Road to Patient-Based Therapy for NSCLC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2-4</style></pages><abstract><style  face="normal" font="default" size="100%">Next-generation sequencing—identifying new molecular targets in non–small cell lung cancer and subsets of patients who are responsive or resistant to novel compounds—will lead to patient-based therapy, the next step from current target-based treatment. The design of clinical trials is evolving to more efficiently test new compounds for new molecular targets and simultaneously develop predictive biomarkers.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>